Celsion closed the most recent trading day at $2.19, moving -1.79% from the previous trading session. This move lagged the S&P 500's daily loss of 1.65%. At the same time, the Dow lost 1.79%, and the tech-heavy Nasdaq lost 1.96%.
Coming into today, shares of the oncology drug development company had lost 7.08% in the past month. In that same time, the Medical sector lost 2.16%, while the S&P 500 gained 1.53%.
Investors will be hoping for strength from CLSN as it approaches its next earnings release, which is expected to be May 15, 2019. On that day, CLSN is projected to report earnings of -$0.25 per share, which would represent no growth from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $0.13 million, unchanged from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of -$0.78 per share and revenue of $0.50 million. These totals would mark changes of -14.71% and 0%, respectively, from last year.
Investors should also note any recent changes to analyst estimates for CLSN. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. CLSN is holding a Zacks Rank of #1 (Strong Buy) right now.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 72, which puts it in the top 29% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
Image: Bigstock
Celsion (CLSN) Dips More Than Broader Markets: What You Should Know
Celsion closed the most recent trading day at $2.19, moving -1.79% from the previous trading session. This move lagged the S&P 500's daily loss of 1.65%. At the same time, the Dow lost 1.79%, and the tech-heavy Nasdaq lost 1.96%.
Coming into today, shares of the oncology drug development company had lost 7.08% in the past month. In that same time, the Medical sector lost 2.16%, while the S&P 500 gained 1.53%.
Investors will be hoping for strength from CLSN as it approaches its next earnings release, which is expected to be May 15, 2019. On that day, CLSN is projected to report earnings of -$0.25 per share, which would represent no growth from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $0.13 million, unchanged from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of -$0.78 per share and revenue of $0.50 million. These totals would mark changes of -14.71% and 0%, respectively, from last year.
Investors should also note any recent changes to analyst estimates for CLSN. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. CLSN is holding a Zacks Rank of #1 (Strong Buy) right now.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 72, which puts it in the top 29% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.